Trump’s plan to impose steep import taxes on pharmaceuticals — some as high as 200% — is drawing sharp warnings from industry experts who fear it could push up drug prices in the United States and trigger shortages
Browsing: Pharmaceuticals
AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, jobs, and production of next-generation medicines.
President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies demanding they lower U.S. drug prices to match international levels, with a September 29 deadline
Moderna has announced that it plans to cut down 10% of its workforce by the end of the year
The U.S.–EU trade agreement sparks uncertainty in the pharmaceutical sector, risking $100 billion in EU investments and disrupting global drug supply chains and innovation.
UnitedHealth Group is under criminal and civil investigation by the DOJ over alleged Medicare fraud, raising serious questions about billing practices and industry oversight.
AstraZeneca has announced plans to invest $50 billion in the U.S. by 2030 amid concerns over tariffs
AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.
U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace
Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 billion
The diet company known as WeightWatchers filed for bankruptcy saying its 62-year-old business model was now under threat amid the rise of weight loss drugs like Ozempic
Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Donald Trump’s tariffs
“With Congress still deliberating the future of telehealth flexibilities, our findings offer crucial evidence that telemedicine can play a modest but meaningful role in lowering U.S. health care’s carbon footprint”
Roche CEO Thomas Schinecker said in a statement on Tuesday that the company’s new $50 billion investment demonstrated its “long-standing commitment to research, development and manufacturing in the US.”
The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all outstanding equity in EsoBiotec on a cash and debt-free basis
Marius Pharmaceuticals, which helped secure FDA removal of Black Box Warning, says regulatory shift marks a milestone for patient access and treatment options.
Big pharma in the United States seems to be pivoting to China for their biotechnology and manufacturing needs
Raising manufacturing and R&D costs would lead to an increase in patient costs as well. It would also make it difficult to raise capital for early-stage healthcare companies
While Journavx marks progress in non-opioid pain treatment, its modest effectiveness highlights the ongoing challenge of finding alternative pain relief solutions.
Bisni Narayanan is the first South Asian-origin President of the CPA since its inception in 1876
Trupill’s Sid Viswanathan is back with a new pharmacy venture focused on HIV, Alchemy.
Tipirneni has been the CEO of Morphic since 2015.